Targeting the RAS upstream and downstream signaling pathway for cancer treatment

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer frequently involves overactivated RAS/RAF/MEK/ERK (MAPK) and PI3K-Akt-mTOR signaling pathways, often driven by genetic mutations.
• Targeted therapy, by inhibiting specific proteins in these pathways, presents a promising strategy for cancer treatment.
• Mutations in RAS, RAF, PTEN, and PIK3CA genes are common drivers of these aberrant signaling pathways.

Purpose of the Study:

• To review small molecule inhibitors targeting specific proteins within the RAS upstream and downstream signaling pathways in cancer.
• To provide an overview of the efficacy of targeted therapies against various cancers.
• To highlight the potential of inhibiting key signaling molecules for cancer treatment.

Main Methods:

• Literature review of small molecule inhibitors targeting RAS/MAPK and PI3K-Akt-mTOR pathways.
• Analysis of studies on targeted therapies including RTK inhibitors, farnesyltransferase inhibitors, and downstream signaling inhibitors.
• Examination of clinical outcomes for inhibitors targeting RAF, MEK, PI3K, AKT, and mTOR.

Main Results:

• RTK inhibitors (e.g., imatinib, afatinib) show efficacy in Non-Small Cell Lung Cancer.
• RAF inhibitors (e.g., vemurafenib) and MEK inhibitors (e.g., trametinib) are effective against cancers with BRAF-V600E mutations.
• Inhibitors of PI3K, AKT, and mTOR pathways demonstrate efficacy in Invasive Breast Cancer, Lymphoma, Neoplasms, and Hematological malignancies.

Conclusions:

• Small molecule inhibitors targeting specific proteins in the RAS and PI3K-Akt-mTOR pathways offer a potent therapeutic strategy for various cancers.
• Targeted inhibition of key signaling molecules demonstrates promising anti-tumor activity both in vitro and in vivo.
• Further development of these targeted therapies holds significant potential for improving cancer treatment outcomes.